Navigation Links
CardioInsight Announces Appointment of Patrick J. Wethington as President & Chief Executive Officer
Date:11/1/2012

CLEVELAND, Nov. 1, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Patrick J. Wethington as President & CEO.

(Logo: http://photos.prnewswire.com/prnh/20121101/DC03452LOGO)

Mr. Wethington brings more than 20 years of cross functional medical device experience in the cardiovascular industry, including sales and marketing leadership roles at Guidant, Endocardial Solutions (acquired by St. Jude Medical), and CHF Solutions (acquired by Gambro).  Most recently, Mr. Wethington served as President and CEO of Hemosphere, which was recently acquired by Cryolife.

"Pat's background in electrophysiology, and his experience bringing novel products to the market will serve as important assets as CardioInsight continues to develop its ECVUE™ platform," said Jim Bullock, the Company's Chairman of the Board.  "Pat has developed a track record of strong leadership throughout his career, and his addition is an important complement to the organization as we further validate ECVUE's exciting potential of unique clinical applications."

"CardioInsight's non-invasive electroanatomic mapping system continues to demonstrate unique clinical impact in the fields of electrophysiology and cardiac rhythm management," said Mr. Wethington. "The growing body of clinical data validates the platform's ability to address multiple high-value opportunities of unmet need, and I am eager to help lead the organization to commercialize these unique clinical solutions."

CardioInsight is currently conducting a limited commercial introduction of its ECVUE non-invasive cardiac mapping system in Europe, demonstrating the unique ability to simplify cardiac mapping procedures and reduce procedure times.  Additionally, clinical studies are being conducted in Europe to expand the use of mapping to new applications, including cardiac resynchronization therapy (CRT) and atrial fibrillation.

About CardioInsight Technologies Inc.
CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart.  The images help physicians map certain heart ailments such as arrhythmias and congestive heart failure.  The Company's ECVUE system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans.  It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart.  To date, CardioInsight has completed more than 425 patient studies at leading clinical centers.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE system in Europe.

For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.


'/>"/>
SOURCE CardioInsight Technologies Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, a ... medical devices, is pleased to announce that its Chief ... selected as a winner of the 2017 Executive Management ... and recognizes driven executives for their creative management ... The awards ceremony and celebration is on March 8, ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... and agreements entered into by the worlds leading healthcare companies. ... Description The Global ... access to partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... , ... February 17, 2017 , ... Park Cities Pet ... Behave” Show on the Pet Life Radio network. The episode, which was posted ... of topics including: what factors led to Park Cities Pet Sitter’s being awarded the ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation ... to further positively impact the health and wellness of our community in San ... our duty to seriously consider releasing our assets beyond our 5% targeted distribution ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):